What is HemaXis?
HemaXis operates at the intersection of medical technology and clinical diagnostics, specializing in the development of innovative micro blood sampling solutions. By leveraging advanced microfluidics, the company effectively simplifies the blood collection process, significantly reducing operational costs for clinical laboratories and pharmaceutical entities. Their core product suite, including the HemaXis DB and HemaXis DX platforms, facilitates the precise collection of whole blood, plasma, and serum. This technology not only enhances patient comfort by minimizing invasive procedures but also improves the accuracy and efficiency of critical applications such as drug monitoring and serology testing, positioning the company as a key player in the evolution of decentralized health monitoring.
How much funding has HemaXis raised?
HemaXis has raised a total of $2.5M across 1 funding round:
Series A
$2.5M
Series A (2017): $2.5M, investors not publicly disclosed
Key Investors in HemaXis
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for HemaXis?
With the infusion of this capital, HemaXis is poised to transition from its current development phase into a broader commercial scaling strategy. The company is expected to prioritize the expansion of its manufacturing capabilities and the strengthening of its distribution networks across global clinical markets. By focusing on operational efficiency and the integration of its sampling technology into existing pharmaceutical workflows, HemaXis aims to solidify its market position. Future growth will likely be driven by the continued adoption of its microfluidic solutions in high-demand sectors, including large-scale clinical trials and routine diagnostic monitoring, as the firm seeks to establish a new standard for patient-centric blood collection.
See full HemaXis company page
